TP53 and neoplasm: This concept is behind the clinical success of Poly-(ADP-ribose)-polymerase (PARP) inhibitors in treatment of BRCA1/2-mutant cancers and has been used to identify therapeutic targets associated with defective tumor suppressors, including p53 (Gurpinar and Vousden, 2015; Patel et al., 2021).